Testing zelquistinel for major depression
Part of Mental health clinical trials.
This study tests whether zelquistinel, an investigational drug, can reduce symptoms of major depressive disorder (a type of clinical depression). It is for people who are currently experiencing a moderate to severe depressive episode and are not taking other antidepressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have been diagnosed with major depressive disorder (clinical depression), and your current episode has lasted between 8 weeks and 2 years.
- Your depression is at least moderately severe (score of 4 or higher on a clinical rating scale).
- You are not taking any FDA-approved antidepressants, antipsychotics, mood stabilizers, or stimulants currently, and you are willing to stop them for at least 2 weeks before the study starts.
- You have not tried two or more different antidepressants that did not work for you during this episode.
- You do not have other major mental health conditions like bipolar disorder, schizophrenia, or PTSD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
This study tests a new medication called BMS-986511 for adults with major depressive disorder. It aims to see if the drug can help relieve depression symptoms more effectively than a placebo.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.